Clinical Program DiscontinuationTurnstone Biologics announced the discontinuation of their lead (and sole) clinical program, TIDAL-01.
Market PerformanceWith the removal of TIDAL-01 from estimates, the price target has been reduced to $1 from $3 and the MP rating is reiterated.
Workforce ReductionA workforce reduction by 60% was recently implemented, indicating potential challenges within the company.